We replace invasive biopsies with non-invasive skin testing. Using cutting-edge next-generation sequencing for epigenetic assessment, we inform on intervention efficacy, rate of biological aging, UV damage, and other skin quality metrics to measure the impact of therapies directly on the human skin.
We use tape-stripping to collect large amounts of biological material easily, and painlessly.
By measuring the change in DNA methylation markers, we can assess the skin’s biological age, inflammation, and sun damage.
We develop predictive biomarkers, identifying optimal responders to specific formulations. This enables a high level of personalization.
